Introduction
The leading cause of morbidity and mortality in Cystic Fibrosis (CF) patients is progressive respiratory dysfunction, partially due to chronic bacterial infections. Pseudomonas aeruginosa is amongst the most frequent pathogens in the respiratory tract of CF adults and causes irreversible lung damages [1] . These patients therefore receive repetitive and prolonged treatments with antipseudomonal antibiotics. Many CF patients also receive longterm treatment with macrolides, based on their known anti-virulence [2] and anti-inflammatory [3] properties, which improve their respiratory function [4] particularly when chronically infected with P. aeruginosa. Macrolides are considered intrinsically inactive against P. aeruginosa, with high (≥ 256 mg/L) minimal inhibitory concentrations (MIC) measured in the recommended conventional broth [5] . This intrinsic resistance is due to the efflux of macrolides out of the bacteria via multidrug efflux systems [6] , among which MexAB-OprM and MexXY-OprM are constitutively expressed in wild-type isolates [7] . Yet, macrolides show low MICs against P. aeruginosa when tested in the presence of serum, bronchoalveolar lavage fluid, or culture media used for eukaryotic cell cultures. Enhanced macrolide activity in these media results from an increased permeability of the bacterial outer membrane [8] . This favors the diffusion of macrolides inside the bacteria, where they repress the expression of OprM, the outer membrane porin coupled to MexAB and MexXY efflux transporters (responsible for macrolide efflux), further increasing the macrolide intrabacterial concentration to a level where clinicallymeaningful activity can be observed [8] .
Whether macrolides also show activity against P. aeruginosa in vivo and contribute thereby to the improvement of lung function in infected CF patients remains to be established. Nevertheless, the large use of macrolides in this population clearly raises the question of the potential risk of selecting macrolide-resistant P. aeruginosa, thereby decreasing their potential usefulness in CF patients, and increasing the global resistance burden.
While macrolide resistance is well described in Gram-positive bacteria (due to target modification [methylation or mutation in the domain V of the 23S rRNA] and/or active efflux [9, 10] ), a single publication reports resistance associated with mutations in the domain V of 23S rRNA of six P. aeruginosa isolates from CF patients treated by macrolides [11] . The extent of this problem is thus largely unknown.
In this study, we determined macrolide activity in a collection of 333 P. aeruginosa isolates from CF patients, using eukaryotic cell culture medium (RPM-1640) in order to detect increases in MICs that could be ascribed to the acquisition of resistance mechanisms (which would have escaped detection if using conventional broth). We included in our analysis 48 isolates collected from intensive care patients suffering from healthcare-associated pneumonia (HAP) [12] , in whom chronic exposure to macrolides could be excluded. We compared conventional macrolides (azithromycin and clarithromycin) to ketolides, the next generation macrolides that are less affected by ribosomal mutations at the domain V of the 23S rRNA, as they also bind to ribosome domain II [13, 14] . Among ketolides, we used telithromycin (registered in 2001 but restricted use due to safety issues), and solithromycin, a new fluoroketolide [15] that successfully completed phase III clinical trials for communityacquired pneumonia [16, 17] .
In brief, we found that CF isolates were significantly less susceptible to macrolides than HAP isolates, with about half of them harboring mutations in the domain V of their 23S rRNA, while no mutations were observed in HAP isolates. MICs of ketolides (especially solithromycin) were less affected by these mutations. Thus, the data document a so far unreported development of resistance to macrolides in P. aeruginosa collected from CF patients and plead for a prudent use of macrolides in this population.
Materials and methods
Bacteria PAO1 was used as a reference and ATCC 27853, as quality control for susceptibility tests.
PAO1-pMES-23S(A2045G) is a PAO1 derivative containing a plasmid pME6031 encoding the whole rRNA operon with the A2045G mutation in the domain V of 23S rRNA [11] .
Clinical isolates (n=333) were randomly collected from 155 patients ( [18] were previously identified by Multi Locus Sequence Typing [19] . Data on file for UK and German isolates also stipulated whether patients were receiving regularly azithromycin (500 mg 3X/week continuously in UK or for intermittent 6 month periods in Germany).
Antibiotics
Antibiotics were obtained as microbiological standards from Teva, Petach Tikva, Israel (clarithromycin, azithromycin), Sanofi-Aventis, Romainville, France (telithromycin), and Cempra Pharmaceuticals, Chapel Hill, NC (solithromycin).
Susceptibility testing
MIC were determined by broth microdilution in CA-MHB (BD Bioscience, Franklin Lakes, NJ) [5] , and RPMI-1640 (Invitrogen, Paisley, UK) adjusted to pH 7.4 and complemented by 10% fetal calf serum [8] . MICs were also measured (i) in the presence of 20 mg/L Phe-Arg-βnaphthylamide (PAβN, broad-spectrum efflux pump inhibitor) and 1 mM MgSO 4 (to strengthen the outer membrane and thereby limit PAβN toxicity [20] ), (ii) 20 U/mL alginate lyase, 0.02% DNase and 20 mM MgCl2 (all from Sigma-Aldrich, St. Louis, MO), or 100 mg/L Proteinase K (ThermoFischer, Waltham, MA).
Assessment of outer membrane permeability
Bacteria were incubated in CA-MHB or RPMI-1640 for 4 hours, after which 25 µM 1-Nphenylnaphthylamine (NPN) was added [8] . Fluorescence was read using a Spectramax (Molecular Devices, Sunnyvale, CA) microplate reader (λexc/λem: 355nm/405nm). Full permeabilization was achieved by adding 3% Triton X-100 [21] 45 minutes before reading.
Gene sequencing of ribosomal RNA and proteins
The genes encoding domains II and V of the 23S ribosomal subunit or the entire ribosomal proteins L4 and L22 were amplified by PCR (table S1 for primers; Eurogentec, Seraing, Belgium) and sequenced (Beckman-Coulter Genomics, Essex, UK). For domain V, we focused on the 625 bp region where mutations have been previously described (A2058G, A2059G and C2611T [22] in the 23S subunit of Escherichia coli [23] , corresponding to positions 2045, 2046 and 2598 in Pseudomonas).
Plasmid construction and transformation in PAO1
The plasmid PAO1-pMES-23S(A2045G) was extracted from its host strain using the GeneJET Plasmid Miniprep Kit (ThermoFischer) and the gene encoding 23S rRNA was reverted back to its wild-type sequence using a Q5® Site-Directed Mutagenesis Kit (NEB, Ipswich, MA), resulting in plasmid pMES-23S(0). This plasmid was used as a template to introduce each of the point mutations observed in the 23S RNA gene (table 1), and the resulting vectors were transformed into PAO1.
Statistical analyses
Statistics were performed using GraphPad Prism 7.01 (GraphPad Sofware Inc., San Diego, CA).
Ethics
According to a decision of the Ethical Committee of the Université catholique de Louvain, the investigations did not fall under the scope of the law on human experimentation since all isolates had been collected during routine sampling and patients' data anonymized before being transmitted to the investigators. Figure 1 shows the MIC distributions of azithromycin (panels a,d) and clarithromycin (panels b,e) as measured in CA-MHB and RPMI-1640 for CF vs. HAP isolates. As previously described [8] , MICs were 1-3 dilutions lower in RPMI-1640 than in CA-MHB. RPMI-1640 is therefore helpful to observe differences in activity amongst antibiotics and/or isolates.
Results

Susceptibility of CF and HAP isolates to macrolides and ketolides
Azithromycin was slightly more active than clarithromycin. HAP isolates were more susceptible than CF isolates, the difference being most apparent for azithromycin in RPMI-1640. All further experiments were performed on a subset of the CF collection selected to cover the whole range of azithromycin MICs. The two conventional macrolides were first compared to two ketolides. Panels c,f show the MIC distributions of solithromycin (compared to azithromycin for the same selected CF isolates in panel c), with the MIC50/90 of clarithromycin, azithromycin, telithromycin, and solithromycin shown in the accompanying table. Ketolides were more potent than macrolides in both media and for both CF and HAP isolates, with solithromycin MIC50/MIC90 being 1-2 log2 dilutions lower than those of telithromycin against CF isolates (in both media) and HAP isolates (in CA-MHB). Yet, CF isolates remained less susceptible to ketolides than HAP isolates.
Outer membrane permeability
We showed that the increased susceptibility of P. aeruginosa to macrolides in RPMI-1640 is due to an increased permeability of the outer membrane in this medium [8] . We therefore investigated whether the lower susceptibility of CF vs. HAP isolates could result from a reduced outer membrane permeability (figure 2).
As anticipated, outer membrane permeability was higher in RPMI-1640 than in CA-MHB, but independently from the origin of the samples.
Efflux pump inhibition
We previously described that intrinsic resistance of P. aeruginosa to macrolides was in part attributable to constitutive expression of efflux pumps [8] . We therefore examined the influence dilutions for HAP isolates, independently of the baseline value (figure 3c-d), designating efflux as the main resistance mechanism in these isolates.
Sequencing of the domain V of 23S rRNA
In Gram-positive bacteria, high level resistance to macrolides is mediated by mutations in their ribosomal target. We therefore sequenced the domain V of 23S rRNA for all isolates presented in figure 1c,e. Mutations were detected in 33 of the 76 sequenced CF isolates (43%), while no mutations were detected in HAP isolates. In CF isolates, 6 different mutations were observed (A2045G, A2045T, A2046G, A2046T, C2598T, C2598G) at 3 specific positions and in 1 to 4 alleles (table 1) .
Effect of mutations on macrolide and ketolide activity
The MIC distributions of azithromycin and solithromycin in isolates showing mutations in domain V of the 23S rRNA were compared to those of non-mutated isolates ( figure 4 ). As expected, mutated isolates (panels a-b) were less susceptible than non-mutated isolates (panels c-d). Interestingly, the MIC distribution of non-mutated isolates from CF patients was superimposable to that of HAP isolates for both drugs and in both media (panels c-d),
suggesting that mutations in part of the CF collection were responsible for the lower susceptibility observed in figure 1.
MICs for individual mutated isolates are shown in table 1 and in figure 4e-f, ordered according to the number of mutated alleles. MICs were in general more elevated in both media against isolates with mutations at position 2045 or 2046 than at position 2598, as well as in isolates with 3-4 mutated alleles. Solithromycin MICs remained low mainly in isolates mutated at position 2598, independently of the number of mutated alleles. One highly resistant isolate harbored two mutations in the 4 alleles.
To confirm the role of these mutations in resistance, PAO1 was transformed by plasmids containing each of the ribosomal mutations observed in clinical isolates. In these transformants, azithromycin MICs were higher than in PAO1, reaching 1024 mg/L for those mutated in positions 2045 and 2046 and 256 mg/L for those mutated in 2598 (values in RPMI-1640). In contrast, ketolide MICs remained low regardless of media.
Additional studies in ketolide resistant isolates
Some CF isolates showed reduced susceptibility to ketolides in RPMI-1640 (table 1) ,
suggesting the presence of other resistance mechanisms. We therefore sequenced the genes encoding the domain II of 23S rRNA and the ribosomal proteins L4 and L22 [24] in the 19
isolates with solithromycin MICs ≥ 64 mg/L, but no mutations were found. A cooperation with efflux could also be ruled out as MICs were not reduced by PAβN for most isolates (table 2) .
CF isolates are often mucoid and easily form biofilms with a matrix rich in alginate, DNA, or proteins that prevents antibiotic access [25] . Solithromycin MICs were therefore also measured in the presence of enzymes degrading these polymeric substances (table 2) .
Alginate lyase, DNAse, or proteinase K brought MICs back to values close to that measured for PAO1 in 14 isolates, among which those mutated in position 2598 were all reverted by alginate lyase.
Impact of azithromycin treatment on susceptibility to macrolides in CF isolates
In contrast to HAP patients, many CF patients are chronically exposed to macrolides, which might have contributed to resistance development. In the UK and German collections for which data on macrolide treatments were available, we compared azithromycin MICs in isolates from patients treated regularly by azithromycin vs. those with no record of chronic azithromycin use ( figure 5 ). In dot plot analysis (panel b), no significant difference but a trend to lower values in the median or geometric mean MIC was noticed for isolates collected from 
Discussion
This study is, to the best of our knowledge, the first to describe the presence of macrolide resistance mechanisms in a large collection of P. aeruginosa from CF patients. It was facilitated by the use of RPMI-1640, in which macrolide MICs are considerably lower than in conventional broth [8] . Approximately half of the sequenced CF isolates did harbor high
MICs and ribosomal mutations that were not observed in HAP isolates.
The low MICs observed for HAP isolates in RPMI-1640 are clearly due to the reduced expression of constitutive efflux transporters (as originally described for laboratory strains and a few clinical isolates [8] Because CF isolates with non-mutated rRNA have an MIC distribution similar to that of HAP isolates, we concluded that macrolide resistance in CF isolates is due to mutations in domain V of 23S rRNA. The detected mutations are located in three previously described positions [11] , but we found here three additional nucleotide changes. Mutations in these positions confer macrolide resistance in other bacterial species [22] , and we confirm using specific mutants that they also increase macrolide MICs in P. aeruginosa. Notably, mutations in 2045 and 2046 confer higher resistance than those in 2598, probably because the first two positions are part of the macrolide binding site while the third site rather alters the conformation of the binding site [14] . We also show that resistance levels are globally higher in isolates harboring mutations in several alleles of the corresponding gene.
Taken together, these findings led us to evaluate the effects of ketolides against CF isolates, as these antibiotics also bind to the domain II of 23S rRNA [14] . As expected, CF isolates are more susceptible to ketolides than to macrolides, with solithromycin being more potent than telithromycin, as in other bacterial species [16] . While most of the isolates showing the A2046T or C2598T mutations had low MICs to solithromycin, those harboring A2045G, A2045T or A2046G mutations generally had higher MICs, in the absence of mutations in 23S rRNA domain II or ribosomal protein L4 or L22. This resistance could be related to the production of extracellular polymeric substances such as alginate, DNA, or proteins, presumably preventing antibiotic penetration.
Importantly, we observed a trend to higher MICs in isolates from azithromycin-treated patients. Specifically in patients infected by the LES clone, mutated isolates with high MICs were more frequently identified from azithromycin-treated patients. This is of concern, as this clone is recognized as multiresistant [27] . Thus, macrolide resistance may, possibly, be more easily selected in the LES background, even though it is acquired by chromosomal mutation and not by gene transfer. Hypermutator variants have been detected, but infrequently in this clone (5-15% [28, 29] ). Cross-infection between patients treated in the same centre is described [18, 30, 31] , especially for epidemic clones [32] [33] [34] , but it is unlikely to markedly contribute to spread resistance here, as mutations are less frequent in LES isolates from nontreated patients.
Macrolides are not given to CF patients for their antibacterial properties against P. aeruginosa. Prescribers may, therefore, consider their use as innocuous with respect to resistance in this organism. Yet, we argue that the highlighted mutations are of concern. First, they may compromise some of the macrolide anti-virulence effects that are directly or indirectly depending on their binding to ribosomes and subsequent protein synthesis inhibition [2, 35] .
Second, they may create a reservoir of resistance, possibly compromising the activity of future drugs acting on the same target. In a broader context, the low but persisting serum concentrations of macrolides (especially azithromycin) may aggravate the risk of resistance development, as suggested for Gram-positive pathogens [36] . Providing high, local concentrations in the lung could help mitigate this risk. In this context, liposomes [37] or formulations for inhalation [38] are currently in development for macrolides. Further studies are also needed to define the potential benefit of fluoroketolides such as solithromycin that accumulate in the epithelial lining fluid and show potent anti-inflammatory properties [39, 40] .
In the current clinical context, our findings may also be of immediate interest for clinicians in their dialogue with microbiologists. For clinicians, we raise the question of the long-term risk/benefit ratio associated with the widespread strategy of chronic use of oral macrolides in CF patients. For microbiologists, we provide an easy phenotypic method The Table below the graphs shows MIC50 and MIC90 values in both conditions. The number of isolates included in the study is indicated in the left panels. The Table shows MIC50 and MIC90 values in both media for mutated (YES) or non-mutated (NO) isolates. The number of isolates included in the study (same as those used in figure 1c,e) is indicated in each panel. 
